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Although immunization has been used for eliciting immune response, here we show that it can also induce immune suppression. When a
DNA vaccine encoding a viral antigen such as the VP1 protein from the foot and mouth disease virus is administered together with its
recombinant protein antigen or a viral preparation containing the same antigen, the immunized animals developed significantly reduced
antigen-specific T cell-mediated responses and became impaired to subsequent rechallenge with the same antigen. The induction of immune
suppression is mediated by suppressor T cells, as demonstrated by an adoptive transfer experiment and mixed lymphocyte reactions. The
induction of immune suppression in immunized animals is also correlated with a shift of cytokine balance, as reflected by an elevated level of
IL-10 and reduced level of IFN-g or IL-2. Hence, co-immunization with DNA- and protein-based vaccines may represent a novel means for
inducing active suppression against untoward immunity.
D 2005 Elsevier Inc. All rights reserved.Keywords: Co-administration; T cells; Suppression; DNA vaccination; Adoptive transfer; Mix lymphocyte reaction; IL-10; FMDVIntroduction
Foot and mouth disease virus (FMDV) is the most
contiguous picornavirus and causes the loss of a large
number of farm animals where it becomes epidemic.
Although conventional vaccines have thus far succeeded
in generating neutralizing antibody important for humoral
response, protection via cellular immunity is still lacking.0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.03.029
Abbreviations: FMDV, foot and mouth disease virus; 146S, inactivated
foot and mouth disease virus; CSFV, classic swine fever virus; HPRT,
hypoxanthine phosphoribosyl transferase; MTT, 3-(4,5-dimethylthiazol-
2-yi)-2,5-diphenyltetrazolium; DTH, delayed-type hypersensitivity.
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vaccination method potentially capable of generating
humoral as well as cellular immunity (Chinsangaram et
al., 1998; Gurunathan et al., 2000; Ward et al., 1997). Used
alone, however, DNA vaccines are often inferior to protein
immunogens, especially for inducing antibody production
(Robinson, 1997) or to attenuated viral vaccines for
inducing cellular immunity in large animals (Benvenisti et
al., 2001; Cedillo-Barron et al., 2001, 2003; Ward et al.,
1997). Furthermore, in animals immunized with a cocktail
of multiple plasmid constructs encoding different antigens,
the antibody response was further reduced due to the
competition among the expressed antigens for the antigen
processing pathway (Sedegah et al., 2004). In contrast,
recent studies have suggested that the combination of DNA-
and protein-based vaccines may hold greater promise. It has
been shown that animals primed with a DNA vaccine and
boosted with a recombinant protein acquired a higher level05) 183 – 191
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alone (Leong et al., 1995). Such prime-boost regimen has
produced encouraging results in several different disease
models (Allen et al., 2000; Amara et al., 2001; Pancholi et
al., 2003; Rogers et al., 2002).
In an attempt to further enhance the efficacy of such
vaccination regimen, we sought to combine DNA and
protein vaccines into a single formulation and use it as
both the priming and boosting agent in a standard prime-
boost regimen. Surprisingly, such co-administration of
DNA and protein vaccines did not produce enhanced
immune protection. Rather, it resulted in impaired cellular
immune responses and the establishment of active immune
suppression. This observation illustrates the complexity of
the interplay between DNA and protein vaccines during
immunization. It also suggests, for the first time, that such
interplays may be exploited not only to elicit immune
protection against harmful pathogens, but also to induce
antigen-specific immune suppression against untoward
immunity.
The notion that immunization may be used to induce
immune tolerance is well documented in the literature.
Particularly, protein-based vaccines have been exploited
for treating autoimmune disease such as multiple scle-
rosis, whereas the more recently introduced DNA-based
vaccines have been developed for alleviating allergy such
as asthma (reviewed in Arnon and Ben-Yedidia, 2003;
Horner et al., 2001). However, thus far, most vaccines
developed in this context are either protein or DNA
alone, but not combined. Moreover, in general, such
vaccines work mainly by redirecting immune polarization
(Th1 vs. Th2) or inducing peripheral deletion and are
limited to passive immune regulatory mechanisms. In
contrast, the present study will show that active immune
suppressive mechanisms can be accessed via the use of a
combined protein/DNA vaccine.Results
Immunization with mixed vaccines induced a humoral
response
To evaluate the efficacy of co-immunization using a
combination of DNA- and protein-based vaccines, we
combined plasmid pcD-VP1 (coding for the FMDV VP1
antigen and hereinafter referred to as ‘‘DNA’’) and a
recombinant VP1 protein (hereinafter referred to as
‘‘VP1’’), or chemically inactivated FMDV (hereinafter
referred to as ‘‘146S’’), into a pre-mixed formulation.
Following a standard prime-boost regimen, we first immu-
nized mice with this formulation as both the priming and
boosting agent, in parallel with control immunizations
involving stand-alone DNA and protein vaccines in various
prime-boost permutations. Sera drawn on days 14, 28, 42,
and 56 after immunization were used to determine the levelof antibody induced. As depicted in Fig. 1A, the titer of total
anti-FMDV antibody induced by priming and boosting with
the DNA/146S or DNA/VP1 pre-mixed vaccines was
comparable to that induced by priming with DNA and
boosting with 146S or VP1, or the same combination
applied in reverse order (data not shown). As expected, the
level of antibody induced by DNA or 146S alone was
significantly lower.
To further analyze this result in the context of protection
against FMDV, we next performed the experiment in cattle.
Half-year-old cattle in groups of four were immunized in
patterns similar to that in mice. A similar robust antibody
response was observed in DNA/146S-immunized cattle
(Fig. 1B). Taken together, these results indicated that the
co-immunization with DNA/146S or DNA/VP1 vaccine
combinations was effective in inducing a humoral response
to the mixed immunogens.
Immunization with mixed vaccines induced an impaired
T cell response
We next determined whether the use of mixed vaccines
would also induce cellular immunity against FMDV. To that
end, splenocytes were isolated from immunized mice on day
14 after the boost injection and stimulated in vitro with 146S
as specific antigen (Fig. 2A), BSA as irrelevant antigen
(data not shown), and Con A as positive control (data not
shown). Surprisingly, the levels of T cell proliferation in
samples from animals primed and boosted with DNA/146S
or DNA/VP1 were among the lowest of all the prime-boost
permutations tested (Fig. 2A).
To determine whether this was due to the mixing of the
two reagents that might have somehow degraded their
performance, we injected the DNA and protein vaccines
individually into two separate legs. Mice immunized this
way again produced a similarly weak T cell response as
indicated by the T cell proliferation assay (Fig. 2B). Taken
together, the data indicate that co-immunization with DNA
and protein vaccines induces an impaired T cell response
and that this outcome depends on the temporal, but not
spatial, co-delivery of the DNA and protein vaccines into
animals. Furthermore, the impaired T cell response was
generated only when the DNA and protein vaccines were
related. Thus, mice co-immunized with a mismatched
vaccine mixture consisting of the DNA construct coding
for the FMDV VP1 and chemically inactivated classic
swine fever virus (CSFV), or CSFV E2 peptide, showed
unimpaired T cell response to the 146S antigen (Fig. 2C).
One possible explanation for these observations was that
the inbred mice used in this experiment might have a
preference in MHC presentation that skewed the immune
response. To rule out this possibility and to also confirm
the result in large animals, we repeated the experiment in
outbreed cattle (Menge et al., 1999). A similar T cell
proliferation assay was performed in cattle with PBMC
obtained on day 40 after the initial immunization. The data
Fig. 1. Antibody production in response to immunization. Total serum anti-FMDVantibody was determined by ELISA, performed in 96-well plates coated with
2 Ag/ml of 146S as the specific antigen. Shown are the antibody titers expressed as absolute ratios of post/naive, with a cutoff set at 2.1. Error bars indicate SD.
(A) Antibody titers in mice (five per group) bled on indicated days after initial immunization. *Indicates the values are statistically significant compared with
the 146S-primed/144S-boosted or DNA-primed/DNA-boosted control groups. **Indicates the value is statistically significant compared with the VP1-primed/
VP1-boosted or DNA-primed/DNA-boosted control groups. (B) Antibody titers in cattle (four per group) bled on days 40 and 100 after the initial
immunization. *Indicates the value is statistically significant compared to the 146S-primed/146S-boosted control group. *Indicates P < 0.05 when compared to
the DNA-primed/146S-boosted group.
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dramatically reduced level of T cell proliferation was
similarly resulted in out-bred cattle that had been co-
immunized with either the DNA/146S or DNA/VP1
vaccine combinations (Fig. 3), thereby rejecting the notion
that the phenomenon is a peculiarity of inbred mice.
Not only T cell proliferation, but also the delayed type
hypersensitivity (DTH) was affected by the administration
of mixed vaccines. As summarized in Table 1, compared
with the various control groups, mice co-immunized with
either DNA/146S or DNA/VP1 showed the lowest level of
DTH in response to a subsequent 146S rechallenge
administered intradermally. In sum, these data suggest that
the FMDV-specific T cell response is significantly impaired
in animals immunized with mixed vaccines.The impaired immune responses are due to active immune
suppression
Mechanistically, the weak immune responses could have
come passively from ineffective immunization. Alterna-
tively, immune suppression might have been induced that
actively attenuated the development of an otherwise full-
fledged immunity against the immunogen. To distinguish
these two possibilities, we performed an adoptive T cell
transfer experiment where splenic T cells from mice
immunized with DNA/146S were transfused into naive
mice on day 7 after the second immunization. The function
of the donor T cells was examined by immunizing the
recipient mice with an optimal regimen that would other-
wise induce a strong immune response in non-transfused
Fig. 2. T cell activation in mice following immunization. Splenocytes were isolated from mice 2 weeks after the second immunization and stimulated in vitro
with 146S as specific antigen. T cell proliferation was determined by the MTT colorimetric method (29) and expressed as stimulation index (defined under
Materials and methods). (A) Result from co-administration of DNA and protein vaccines at the same site. (B) Result from administration of the DNAvaccine in
one leg and the protein vaccine in the other leg. (C) Result from mice co-administrated with the DNA vaccine coding for VP1 mixed with the CSFV protein
antigens, 146S, or CSFV E2 peptide. *Indicates P < 0.05 when compared to the other groups.
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quently sacrificed and splenocytes were isolated and
assayed for antigen-specific T cell proliferation as described
earlier. As depicted in Fig. 4, mice receiving the DNA/146S-
immunized donor T cells produced an impaired proliferative
response despite having undergone optimal immunization.
In fact, the level of T cell activity in this group was similar
to that in donor mice (Fig. 4, group 5). In contrast, other
control groups that received control-immunized donor cells,
or no donor cells at all, showed significantly higher levels of
T cell proliferation as normally expected. The data thus
demonstrated the presence of suppressor T cells in the DNA/
146S-immunized mice that were capable of conferringdominant suppression upon adoptive transfer. The data also
confirmed that these suppressor T cells were induced by co-
immunization with DNA/146S, but not other immunization
regimens.
To date, most suppressor T cells have been shown to
inhibit the activation of other T cells in a non-antigen-
specific manner and cause a global impairment of T cell
proliferation. Having demonstrated the presence of suppres-
sor T cells in immunized mice, we further determined
whether these particular cells function in a similar manner
using a one-way mixed lymphocyte reaction assay (MLR).
Enriched T cells obtained from immunized BALB/c mice
were mixed with mitomycin C-treated accessory cells from
Fig. 3. T cell activation in cattle following immunization. PBMCs were
isolated from cattle on day 40 after the initial immunization by Ficoll-Plaque
density gradient centrifugation and stimulated in vitro with 146S as specific
antigen, BSA as irrelevant antigen, and Con A as positive control (data not
shown). T cell proliferation was determined by the MTT colorimetric
method and expressed as stimulation index. Error bars indicate SD.
Fig. 4. Suppression of T cell activity in recipient mice. BALB/c mice were
divided into three donor groups (three per group) and immunized with
DNA alone, DNA/146S, or saline solution, respectively. CD3+ T cells
prepared from the spleen of each group on day 7 after the second
immunization were adoptive-transferred, respectively, into three groups of
naive BALB/c mice via footpad injection (1  106 T cells per foot). All
the recipient mice were then immunized with DNA and 146S on days 2
and 15 (prime-boost). The activation of T cells in these animals following
the immunization was examined on day 21 by the T cell proliferation assay
described before (Fig. 2). Mice immunized twice with DNA or co-
immunized twice with DNA/146S were also included as control groups for
the donors. *Indicates P < 0.05 when compared to the all other groups.
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3 days. The activity of the BALB/c responder T cells against
the C57BL/6 stimulator cells was then determined by the
proliferation assay. As depicted in Fig. 5, T cells from DNA/
146S immunized BALB/c mice, which were shown to
suppress the antigen-specific proliferation to the 146S
antigen before (Figs. 2 and 4), were also able to suppress
non-antigen-specific T cell proliferation to broad allogeneic
stimulation. In comparison, vigorous T cell proliferation was
seen in MLR when responder T cells were from DNA-
immunized BALB/c (non-suppressive) or from saline-
immunized BALB/c. This result indicates that the suppres-
sor cells generated with DNA/146S co-immunization can
function in a non-antigen-specific manner.
IL-10 was induced by mixed vaccines
In conjunction with the presence of suppressor T cells,
mice immunized with mixed vaccines developed a cytokine
pattern consistent with immune suppression. Semi-quanti-Table 1
Effect of mixed vaccines on DTHa
Immunization Thickness of footpad (mm)b
Prime Boost Left foot
24 h 48 h
DNA/146S DNA/146S 1.7 T 0.1 1.7 T 0.1
DNA 146S 1.6 T 0.0 1.9 T 0.5
146S DNA 1.7 T 0.2 2.0 T 0.4
DNA/VP1 DNA//VP1 1.6 T 0.0 1.7 T 0.1
DNA VP1 1.6 T 0.0 1.7 T 0.1
VP1 DNA 1.6 T 0.1 1.8 T 0.0
a Mice were immunized by priming and boosting with the indicated vaccine combin
was injected intradermally into the right footpad; PBS (10 Al) into the left footpad
b Thickness was measured at 24, 48, and 72 h after the injection of antigen. Sho
* P < 0.05 when compared to the other groups.tative RT-PCR performed on spleen cells isolated from mice
immunized with DNA/146S or DNA/VP1 showed that the
IL-10 mRNAwas up-regulated, whereas the IL-2 and IFN-g
mRNAs were down-regulated (Fig. 6). In contrast, IL-10Right foot
72 h 24 h 48 h 72 h
1.6 T 0.1 2.8 T 0.2* 3.4 T 0.2* 2.3 T 0.1*
1.6 T 0.1 4.8 T 0.9 5.4 T 0.1 3.2 T 0.1
1.6 T 0.2 4.1 T 0.2 4.8 T 0.2 3.1 T 0.3
1.5 T 0.0 2.8 T 0.1* 3.4 T 0.1* 2.5 T 0.2
1.6 T 0.0 3.5 T 0.2 4.6 T 0.0 3.0 T 0.1
1.5 T 0.1 3.6 T 0.2 4.5 T 0.2 2.8 T 0.3
ations and challenged on day 7 after the boost injection. 146S (10 Ag in 10 Al)
as negative control.
wn are means T SD (n = 3).
Fig. 5. Mixed lymphocyte reactions. BALB/c mice were divided into three groups (three per group) and immunized twice, following the prime-boost regimen
(Materials and methods), with DNA alone (open bar), DNA/146S (dotted bar), or saline solution (hatched bar), respectively. Fourteen days after the second
immunization, T cells from the immunized mice (pooled within the group) were enriched by a nylon wool column, mixed with mitomycin C-treated accessory
cells from naive C57B/6 mice at indicated ratios, and plated at 3  105 total cells per well. T cell proliferation was determined by the MTT method described
before (Fig. 2). *Indicates P < 0.05 when compared to the other groups; **indicates P < 0.01 when compared to the other groups.
Fig. 6. Semi-quantitative RT-PCR assay for cytokine gene expression.
Total RNA was isolated from the spleens of immunized or normal mice
(three per group) on day 7 after the boost. (A) The levels of cytokines IL-
10, IL-2, and IFN-g were semi-quantitatively measured by RT-PCR
relative to a competitive template, pQRS (Reiner et al., 1993). Specific
and competitor products from each PCR reaction were visualized by
agarose gel electrophoresis and ethidium bromide staining. (B) Bands
were scanned and quantified with the use of Quantity One 4.2.0 (Bio-
Rad). Shown are band intensities expressed in an arbitrary unit, with the
dashed line indicating the average intensity of the band produced from the
competitor (internal control). 1, DNA-primed and 146S-boosted; 2, co-
immunized with DNA/146S; 3, DNA-primed and VP1-boosted; 4, co-
immunized with DNA/VP1.
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in control animals primed with DNA and boosted a protein,
or vise versa (data not shown). This result indicates that the
effect of mixed vaccines may be partly mediated by a shift
of balance in cytokines.Discussion
Initially, we evaluated the co-administration of DNA and
protein vaccines for the purpose of developing more
efficient vaccination regimen. To our surprise, such combi-
nation instead induced immune suppression, as evident from
the impaired antigen-specific T cell activity (Figs. 2 and 3),
reduced antigen-specific DTH (Table 1), and up-regulation
of IL-10 and down-regulation of IFN-g and IL-2 (Fig. 6).
Additionally, anti-FMDV antibody production remained
normal (Fig. 1). Such broad suppression apparently involves
the induction of suppressor T cells, generated after the co-
immunization with mixed vaccines and transferable to naive
animals (Fig. 4). One-way mixed lymphocyte reaction assay
further showed that the induced suppressor T cells can
function in a non-antigen-specific manner (Fig. 5), typical of
most suppressor T cells known to date. The suppressive
mechanism may also involve the induction of the suppres-
sive cytokine IL-10 (Fig. 6). IL-10 has been implicated in
the down-regulation of the Th1 cytokines such as IL-12 and
IL-18 (reviewed in Akbari et al., 2003; Shevach, 2002).
The current understanding of the regulatory T cells
encompasses many cell types that differ in both lineage
and mode of action. The major type of suppressor T cells, the
CD4+CD25+ T cells, is derived from the thymus and capable
of inhibiting the activation of effector T cells via direct cell–
cell contact (Nagler-Anderson et al., 2004; Shevach, 2002).
These cells have also been shown to secrete IL-10, which in
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matory reactions (Maloy et al., 2003). Another type of
suppressor cells, known as Tr1, can be generated from
murine and human CD4+ T cells by repeated in vitro
stimulation and functions primarily by secreting high levels
of IL-10 (Dieckmann et al., 2002). Yet another type of
suppressor T cells, known as Tr3, is induced by oral
administration of antigen and suppresses immune reactions
via the production of TGF-h (Weiner, 2001). Lastly, certain
anergic T cells have also been found to suppress the function
of antigen presenting cells, thereby blocking the induction of
immune responses (Vendetti et al., 2000). Whether the
suppressor T cells generated via co-immunization, as
presented in this study, belong to any of these previously
documented cell types is unclear. It is also possible that more
than one type of suppressor cells may be generated after the
co-immunization. Neither do we know at what frequency the
suppressor T cells are induced and persist over time
following the immunization. More elaborate further exper-
imentation will be needed in order to sort out this
complicated issue. Particularly, a refined adoptive transfer
system should be developed where the donor Tcells will bear
a unique surface marker, distinguishable from the T cells of
the recipient. Such system would facilitate more detailed
study of the basic immunology of the suppressor T cells by
allowing tracking of these cells after their transfusion.
This is not the first time that a vaccine designed to induce
immune protection turns out causing immune suppression.
In fact, protein- and DNA-based vaccines have been used to
deliberately suppress autoimmune and allergic reactions
such as multiple sclerosis and asthma (see reviews Arnon
and Ben-Yedidia, 2003; Horner et al., 2001). Thus far,
however, most vaccines developed in this context have been
aimed at redirecting immune polarization (Th1 vs. Th2) or
inducing peripheral deletion, and are therefore limited to
passive immune regulatory mechanisms. The present study
is significant in that it shows that active immune-suppres-
sive mechanisms can also be accessed via the use of a
combined protein/DNA vaccine. That said, however, the
finding made here with the FMDV vaccines needs to be
further explored in order to determine whether it would hold
true with other vaccines.
It should be noted that the induction of suppression does
not depend on the mixing of two vaccines. In fact, the
vaccines may be delivered separately at two distant sites and
remain effective (Fig. 2B). What is required, however, is the
timing—that they must be delivered at the same time. This
suggests that the simultaneous presentation of DNA and
protein vaccines to the immune system is likely to be the
key factor into the induction of suppression. Furthermore,
we have also tested the requirement for the DNA vaccine to
encode a protein identical to that comprising the co-injected
protein vaccine. When the DNA construct coding for the
FMDV VP1 was co-delivered with a protein or peptide
preparation of the CSFV, no suppression of T cell
proliferation was observed (Fig. 2C). Thus, the requirementfor the DNA and protein vaccines to be related at the protein
level seems to be strict. Similar observations were made
previously in a different context from co-delivery of the
human hepatitis B virus core protein or peptide with plasmid
encoded the S antigen (Kwissa et al., 2003; Riedl et al.,
2004). On the other hand, a recent study of animals
immunized with a cocktail of plasmids encoding different
protein antigens shows that the simultaneous exposure of
animals to mixed protein antigens can give rise to a
dampened antibody response. Such result, however, is not
due to active immune suppression as we see in this study,
but is rather caused by the competition among the expressed
antigens for the antigen processing pathway within the host
(Sedegah et al., 2004).
The interplay between DNA and protein vaccines during
the course of immunization is complex. Although the
combination of the two has in the past generally resulted
in enhanced efficacy in inducing protective immunity
against pathogens, this is the first time that such combina-
tion has been shown to induce immune suppression.
Uncovering such complexity will undoubtedly lead to better
understanding of the mechanisms controlling the balance
between immune activation and suppression, and ultimately,
better designed vaccine strategies for immune manipulation.Materials and methods
Animals
Female BALB/c and C57BL/6 mice of 4–6 weeks of age
were purchased from Beijing Vital Laboratory Animal
Technology Company, Ltd. (Beijing, China), and main-
tained under pathogen-free conditions. Male cattle of 4–6
mouths of age that were tested negative for anti-FMDV
antibody were selected and maintained in a cattle farm.
Immunogen and immunization
Plasmid pcD-VP1 coding for the FMDV VP1 was maxi-
preped by alkaline method and subsequently purified by
PEG8000 precipitation (Sambrook et al., 1989), diluted in
saline solution, and used as the DNA vaccine (Jin et al.,
2004a) (hereinafter referred to as ‘‘DNA’’). Levamisole–
HCL (LMS, Sigma, St. Louis) used as adjuvant was
dissolved in saline at 2% and mixed with DNA solution
to 1% (v/v) for mice and 5% (v/v) for cattle (Jin et al.,
2004a). For immunization, mice were injected intramuscu-
larly with the DNA formulation containing 50 Ag DNA;
cattle were injected similarly with 200 Ag DNA. The 146S
antigen (chemically inactivated FMDV, hereinafter referred
to as ‘‘146S’’) was obtained from Lanzhou Institute of
Veterinary Medicine (Lanzhou, China) and injected intra-
muscularly, after emulsified with mineral oil, into mice (20
Ag) or cattle (50 Ag). The recombinant VP1 protein (Jin et
al., 2004a, 2004b) (hereinafter referred to as ‘‘VP1’’) was
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VP1 and also injected intramuscularly in emulsified form
into mice (20 Ag) or cattle (50 Ag). The chemically
inactivated classic swine fever virus (CSFV) was obtained
from China Institute for Veterinary Drug Control. These
antigens were injected intramuscularly, after emulsifying
with mineral oil, into mice (20 Ag) or cattle (50 Ag). The
CSFV E2 peptide (residues 146–157) was synthesized by
GL Biochem Ltd (Shanghai, China), emulsified with
mineral oil, and injected intramuscularly into mice (50
Ag). For co-administration of DNA/146S or DNA/VP1, the
injection solutions were composed of 50 Ag of DNA and 20
Ag of indicated protein (for mice) or 200 Ag of DNA and 50
Ag protein (for cattle). The schedule for the prime-boost
protocol was performed on day 0 and day 14.
Detection of anti-FMDV antibody
ELISA was performed following a previously published
procedure (Biragyn et al., 2002). Serum antibody titers were
defined as the highest dilution that gave an above 2.1 ratio
between testing serum and the naive negative control.
T cell proliferation
For mice, the animals were sacrificed 14 days after the
second immunization and single-cell suspensions of
enriched T cells were prepared as described previously
(Mosmann, 1983). The T cells were cultured at 5  104
cells/well in triplicate in 96-well plates containing RPMI-
10/5% FCS for 24 h. The cells were then stimulated for 48 h
with 5 Ag/ml of Con A (positive control), 2 Ag/ml of 146S
(specific antigen), 2 Ag/ml of BSA (irrelevant antigen), or
no antigen (negative control). Following the stimulation,
cell proliferation was assessed by addition of 20 Al of an
MTT (Sigma) solution, prepared in PBS at 5 mg/ml (pH
7.2), to each well. After 2 h of incubation, 100 Al of SDS–
DMF was added to each well and the assay was allowed to
develop overnight. The plates were read at 570 nm
(Mosmann, 1983; Yutaka et al., 1999). For cattle, PBMCs
were isolated on day 40 and stimulated in culture with Con
A, 146S, or BSA (Yutaka et al., 1999). Pooled PBMCs from
two naive cattle were stimulated with 146S in vitro to serve
as sham control. The proliferation of PBMC was assessed
by the same MTT method. Data are expressed as the
stimulation index (SI), calculated as the mean reading of
triplicate wells stimulated with an antigen, divided by the
mean reading of triplicate wells stimulated with medium.
Antigen-specific DTH
Seven days after the second immunization (boost), mice
in groups of five were challenged with 146S, or saline
solution as control, at the right footpad. The thickness of the
footpad was measured at 24, 48, and 72 h later using an
engineer’s micrometer.Adoptive transfer
BALB/c mice in groups of three were immunized
respectively with various vaccine combinations as described
before. The animals were then sacrificed on day 7 after the
second immunization and the pooled splenocytes (within
each group) were subject to panning on plates coated with
anti-CD3 mAb (Serotec, Oxford, UK). The panned CD3+ T
cells were collected and used as donor cells. The donor cells
were injected into the footpads of naive BALB/c mice at
1  106 cells/mouse. The recipient mice were immunized on
days 2 and 15 following the adoptive transfer and sacrificed
on day 21. T cells were isolated from the spleens and
assayed for proliferation as described before.
Mixed lymphocytes reaction
BALB/c mice in groups of three were immunized
respectively with various vaccine regimens as described
before. T cells were then isolated on day 14 from the spleens
of immunized mice using a nylon wool column and pooled
within each group. Accessory cells used as stimulator were
prepared from naive C57BL/6 mice and treated with
mitomycin C for 30 min at 37 -C before use. The BALB/
c T cells were mixed with the C57BL/6 stimulator cells at
various ratios and plated in triplicate wells at 5  105 total
cells per well in RPMI 1640 with 5% FCS. At 72 h, the cell
proliferation of the co-culture was assessed by the MTT
assay as described above.
Cytokine assay
Cytokine levels were determined by semi-quantitative
RT-PCR in the presence of a known amount of competitor
as a reference as previously described (Reiner et al., 1993).
Total RNAwas isolated on day 7 after the boost, from which
cDNAwas synthesized using the AMV reverse transcriptase
and a (dT)18 primer. Competitive PCR was performed with
optimized primers specific for housekeeping or cytokine
genes as described previously (Jin et al., 2004a) with
modifications. The PCR products were analyzed by agarose
gels stained with ethidium bromide and quantified using the
Quantity One software (Bio-Rad, CA).
Statistic analysis
One-sided Student’s t test was performed. Differences
were deemed statistically significant if P < 0.05.Acknowledgments
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